1 |
Armstrong EJ, Feldman DN, Wang TY, Kaltenbach LA, Yeo KK, Wong SC, et al. Clinical presentation, management, and outcomes of angiographically documented early, late, and very late stent thrombosis. J Am Coll Cardiol Intv. 2012; 5:131-40.
doi: 10.1016/j.jcin.2011.10.013
|
2 |
Gori T, Polimeni A, Indolfi C, Räber L, Adriaenssens T, Münzel T. Predictors of stent thrombosis and their implications for clinical practice. Nat Rev Cardiol. 2019; 16(4):243-56.
doi: 10.1038/s41569-018-0118-5
|
3 |
Almalla M, Schröder J, Hennings V, Marx N, Hoffmann R. Long-term outcome after angiographically proven coronary stent thrombosis. Am J Cardiol. 2013; 111:1289-94.
doi: 10.1016/j.amjcard.2013.01.268
|
4 |
Genereux P, Stone GW, Harrington RA, Gibson CM, Steg PG, Brener SJ, et al. Impact of intra-procedural stent thrombosis during percutaneous coronary intervention: insights from the CHAMPION-PHOENIX trial. J Am Coll Cardiol. 2014; 63:619-29.
doi: 10.1016/j.jacc.2013.10.022
|
5 |
Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007; 115:2344-51.
doi: 10.1161/CIRCULATIONAHA.106.685313
|
6 |
Kimura T, Morimoto T, Kozuma K, Honda Y, Kume T, Aizawa T, et al. Comparisons of baseline demographics, clinical presentation, and long-term outcome among patients with early, late, and very late stent thrombosis of sirolimus-eluting stents: observations from the Registry of Stent Thrombosis for Review and Reevaluation (RESTART). Circulation. 2010; 122(1):52-61.
doi: 10.1161/CIRCULATIONAHA.109.903955
|
7 |
Nakazawa G. Stent thrombosis of drug eluting stent: pathological perspective. J Cardiol. 2011; 58(2):84-91.
doi: 10.1016/j.jjcc.2011.07.004
pmid: 21839616
|
8 |
Garg S, Sarno G, Girasis C, Vranckx P, de Vries T, Swart M, et al. A patient-level pooled analysis assessing the impact of the SYNTAX (Synergy between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery) score on 1-year clinical outcomes in 6,508 patients enrolled in contemporary coronary stent trials. JACC Cardiovasc Interv. 2011; 4(6):645-53.
doi: 10.1016/j.jcin.2011.02.018
|
9 |
Garg S, Sarno G, Serruys PW, Rodriguez AE, Bolognese L, Anselmi M, et al. Prediction of 1-year clinical outcomes using the SYNTAX score in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a substudy of the STRATEGY (single high-dose bolus tirofiban and sirolimus-eluting stent versus abciximab and bare-metal stent in acute myocardial infarction) and MULTISTRATEGY (multicenter evaluation of single high-dose bolus tirofiban versus abciximab with sirolimus-eluting stent or bare-metal stent in acute myocardial infarction study) trials. JACC Cardiovasc Interv. 2011; 4(1):66-75.
doi: 10.1016/j.jcin.2010.09.017
|
10 |
Palmerini T, Genereux P, Caixeta A, Cristea E, Lansky A, Mehran R, et al. Prognostic value of the SYNTAX score in patients with acute coronary syndromes undergoing percutaneous coronary intervention: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage StrategY) trial. J Am Coll Cardiol. 2011; 57:2389-97.
doi: 10.1016/j.jacc.2011.02.032
|
11 |
Palmerini T, Caixeta A, Genereux P, Cristea E, Lansky A, Mehran R, et al. Comparison of clinical and angiographic prognostic risk scores in patients with acute coronary syndromes: analysis from the Acute Catheterization and Urgent Intervention Triage StrategY (ACUITY) trial. Am Heart J. 2012;163(3):383-91, 391.e1-5.
doi: 10.1016/j.ahj.2011.11.010
|
12 |
Mehran R, Baber U, Steg PG, Ariti C, Weisz G, Witzenbichler B, et al. Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2-year results from a prospective observational study. Lancet. 2013; 382(9906):1714-22.
doi: 10.1016/S0140-6736(13)61720-1
|
13 |
Sorrentino S, Giustino G, Baber U, Sartori S, Cohen DJ, Henry TD, et al. Dual antiplatelet therapy cessation and adverse events after drug-eluting stent implantation in patients at high risk for atherothrombosis (from the PARIS Registry). Am J Cardiol. 2018; 122(10):1638-46.
doi: 10.1016/j.amjcard.2018.07.041
|
14 |
Sharma A, Lavie CJ, Sharma SK, Garg A, Vallakati A, Mukherjee D, et al. Duration of dual antiplatelet therapy after drug-eluting stent implantation in patients with and without acute coronary syndrome: a systematic review of randomized controlled trials. Mayo Clin Proc. 2016; 91(8):1084-93.
doi: 10.1016/j.mayocp.2016.06.004
|